Abstract:Background: Recombinant hirudin (r-hirudin) is a highly specific and selective thrombin inhibitor. Since 1997, it has been approved for the treatment of heparin-induced thrombocytopenia (HIT type II). Renal function impairment drastically prolongs the elimination half-life time. In cases of bleeding or overdosage, there is currently no antidote available. Hemofiltration has been reported to be useful in r-hirudin elimination. In this study, we determined sieving coefficients (SCs) and drug clearances for two different hemofilters currently used in clinical medicine and intensive care. Methods: We developed an in vitro postdilution hemofiltration model using 500 ml heparinized (2 IU unfractionated heparin/ml) fresh human blood and bicarbonate substitution fluid. The investigated membranes were high-flux polysulfone F50 (1.0 m2, Fresenius) and AN69 Nephral 200 (1.05 m2, Hospal Cobe). After equilibration, a bolus of Lepirudin was injected into the postfilter port to achieve a r-hirudin blood level of approximately 15 microg/ml. Serial blood and ultrafiltrate samples were taken for the determination of hirudin levels (chromogenic assay) and control parameters. SC and clearances were calculated according to standard formulae. Results: The observed SCs and clearances differed significantly between F50 and Nephral 200 (0.60+/-0.17 and 21.0+/-5.9 ml/min, respectively, vs. 0.44+/-0.09 and 15.5+/-3.0 ml/min, respectively; P = 0.001). The determination of prothrombin fragments showed no coagulation activation during the experiments. The hematocrit values remained stable. Conclusions: Our data show that r-hirudin can be eliminated by hemofiltration. The elimination obviously depends on the membrane material with high-flux polysulfone being more effective than AN69. These findings may be important in cases of overdosage and for r-hirudin dosage guidelines in continuous hemofiltration.

Degradation of Recombinant Hirudin-2 in Nasal Mucosa of Rabbits in Vitro

Nasal recombinant hirudin-2 delivery: absorption and its mechanism in vivo and in vitro studies.

The Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin-2 Nasal Spray

Pharmacokinetic study with N-Ile1-Thr2-63-desulfato-r-hirudin in rabbits by means of bioassay

Correction: Evaluation of a Novel Thermosensitive Heparin-Poloxamer Hydrogel for Improving Vascular Anastomosis Quality and Safety in a Rabbit Model.

Investigation on recombinant hirudin via oral route.

Pharmacodynamics and Pharmacokinetics of Recombinant Hirudin Via Four Non-Parenteral Routes

Studies on the Nasal Epithelium Toxicity of Adjuvants and Recombination Hirudin (rhv2) Nasal Spary

Expression, Purification and Characterization of the Recombinant Hirudin Variant Iii in the Bacillus Subtilis

Permeation-enhancing Effects of Chitosan Formulations on Recombinant Hirudin-2 by Nasal Delivery in Vitro and in Vivo.

The Anticoagulant Effect of Recombinant Hirudin 2 after Orally Administrated to Rats

Preparation of Hirudin Gelatin Microsphere and Its Evaluation of Release in Vitro

Hirudin: Administration Routes and Formulations

Effect of Apoptosis of rVvhA on HUVEC and the Related Mechanism

Determination of Lidocaine Hydrochloride in Rabbit Plasma and Pharmacokinetics of Different Routes of Administration

Studies on the Separation and Purification of Recombinant Hirudin Variant 3 from the Bacillus Subtilis

Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes.

The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits

[Preparation of Raav2/hfix and Experimentally Application to Gene Therapy for Hemophilia B].

Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes

Controlled Delivery of Recombinant Hirudin Based on Thermo-Sensitive Pluronic® F127 Hydrogel for Subcutaneous Administration: in Vitro and in Vivo Characterization